Founded in 1993, OTS Holdings has established itself as a brand builder and food manufacturing group in the consumer industry with a strong niche in ready-to-eat and ready-to-cook meat products. OTS Holdings operates the flagship brands of “Golden Bridge” and “Kelly’s”.
In May 2021, 21 SGX primary-listed stocks bought back 36 million shares for a total consideration of S$91.1 million. OCBC commenced a new buyback mandate in May, acquiring 4.21 million shares at an average price of S$12.16 per share. The preceding mandate saw OCBC acquire 6.66 million shares which represented 0.15 per cent of its outstanding shares excluding treasury shares.
During this earnings season to date, 17 S-REITs have averaged DPU growth of 25%, with SPH REIT, Mapletree Commercial Trust, AIMS APAC REIT, ARA LOGOS Logistics Trust and Frasers Centrepoint Trust, among the S-REITs posting the highest y-o-y DPU growth.
In April 2021, 16 SGX primary-listed stocks bought back 23 million shares for a total consideration of S$48.5 million. Of the stocks that conducted buybacks in April, Global Investments has bought back the largest percentage of its issued shares on the current mandate.
Econ Healthcare (Asia) Limited (SGX:EHG), a private nursing home operator in Singapore and Malaysia, made its debut on the SGX Catalist. It currently operates 10 medicare centres and nursing homes in Singapore, Malaysia and China, with the establishment of Chongqing Nursing Home, which is expected to commence operations in 2021.
On 17 April, the 7-day rolling average of daily new confirmed cases of COVID-19 moved above its January 2021 high, to 766,231 cases. SGX listed medical supplier stocks - Top Glove, Medtecs International, Riverstone, UG Healthcare and Aspen Group have all gained in the April month to 16 April, averaging 11.7% gains over the 11 sessions.
Effective 13 April 2021, Frasers Logistics & Commercial Trust has joined the STI with an indicative weight of 1.3%, taking the number of REITs within the STI to 7, with a combined Index weight of ~15%. This makes REITs the 3rd largest Sector by Index weight of the STI after Financials and Industrials.
Singapore’s 21 most traded non-STI stocks in the 2021 year-to-date have traded S$220 million in turnover a day, 15% of the total turnover of all stocks and trusts listed on SGX. Thomson Medical, iFAST & ISDN led the 21 stocks in the year-to-date.
For 1Q21, there were 37 SGX primary-listed stocks that conducted buybacks over the quarter, with consideration totaling S$134 million. Over the quarter, the Straits Times Index (STI) gained 11.3%, and the buyback consideration represented 0.01 per cent of the S$943.8 billion in market capitalisation of all stocks listed on SGX as of 31 March.
With 3 sessions remaining for the March 2021, the STI has generated an 11.1% price gain year-to-date, outpacing all the major world benchmarks. The 1Q21 quarter is also poised to be the STI’s best start to a calendar year since 2012. As many as 11 of the STI stocks - Jardine Strategic, Yangzijiang Shipbuilding, Singapore Airlines, Hongkong Land, Jardine Matheson, CapitaLand, OCBC, Wilmar International, Jardine Cycle & Carriage, DBS and UOB have generated double digit gains in the quarter-to-date.
These articles are provided by SGX My Gateway.
SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.
These articles are not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the “SGX Group Companies”) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.